

Ormutivimab

Cat. No.:	HY-P99792
CAS No.:	2449086-91-1
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model ^[1] [2].								
In Vivo	<p>Ormutivimab (20 IU/kg; i.m.; single dose) protects beagles from a lethal challenge of street RABV BD06^[1]. Ormutivimab (20 IU/kg, 100 IU/kg; i.m.; single dose) protects challenged Kunming mice against various rabies virus^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Balb/c mice challenge model with rabies virus^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 IU/kg, 100 IU/kg</td> </tr> <tr> <td>Administration:</td> <td>Intramuscular injection; single dose after 4 hr after infection</td> </tr> <tr> <td>Result:</td> <td>Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.</td> </tr> </table>	Animal Model:	Balb/c mice challenge model with rabies virus ^[1]	Dosage:	20 IU/kg, 100 IU/kg	Administration:	Intramuscular injection; single dose after 4 hr after infection	Result:	Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.
Animal Model:	Balb/c mice challenge model with rabies virus ^[1]								
Dosage:	20 IU/kg, 100 IU/kg								
Administration:	Intramuscular injection; single dose after 4 hr after infection								
Result:	Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.								

REFERENCES

[1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. *Travel Med Infect Dis.* 2022 Mar-Apr;46:102267.

[2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. *Vaccines (Basel).* 2022 Jul 29;10(8):1218.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA